| Value | ₹42.00 Cr |
|---|
NSE filing, NSE: INFINIUM. Summary written from the filing by ALFA Finder's alert engine.
Infinium Pharmachem Ltd: key numbers
- Share price
- ₹281.00
- Market cap
- ₹391.0 Cr
- Revenue (annual)
- ₹189.6 Cr
- Net profit (annual)
- ₹12.15 Cr
- P/E (TTM)
- 32.2×Sector 45.9×
- Promoter holding
- 64.91%
- FII holding
- 0.00%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Infinium Pharmachem Ltd
All →Infinium Pharmachem Other Announcement
Infinium Pharmachem Limited filed its quarterly SEBI Regulation 74(5) compliance certificate for the period ending September 30, 2026, confirming all shares are held in demat form.
Infinium Pharmachem SME to Main Board Migration
Infinium Pharmachem Limited submitted its Annual Secretarial Compliance Report for 2026. This filing supports the company's application to migrate from the NSE SME Emerge platform to the Main Board.
Infinium Pharmachem Annual General Meeting
Infinium Pharmachem Limited announced that the resolution for migrating its equity shares from the NSE Emerge platform to the mainboard was passed via postal ballot.
Infinium Pharmachem Credit Rating
ICRA assigned a new [ICRA]BBB (Stable) rating to Infinium Pharmachem's ₹52.20 Crore credit facilities. The assignment covers cash credit, term loans, and unallocated limits from ICICI Bank and SBI.
Infinium Pharmachem Annual General Meeting
Infinium Pharmachem Limited held its 22nd Annual General Meeting on September 17, 2026. Shareholders transacted ordinary and special business, including director appointments and remuneration revisions.
Infinium Pharmachem SME to Main Board Migration
Infinium Pharmachem Limited issued a postal ballot notice to seek shareholder approval for migrating its equity shares from the NSE Emerge platform to the main board.
Other fund raise announcements
All →Rite Zone Chemcon India Fund Raise of ₹6.58 Cr
Rite Zone Chemcon India announced a preferential issue of 27,69,730 equity shares to 11 investors at Rs.24 each, raising about Rs.6.58 Crore. The approval awaits a shareholder vote on 23 November 2026.
- Value
- ₹6.58 Cr
Sudarshan Pharma Industries Fund Raise of ₹72 Cr
Sudarshan Pharma's board approved up to Rs. 72 Crore of preferential convertible warrants for promoters Hemal and Sachin Mehta. Shareholder approval will be sought at an EGM.
- Value
- ₹72.00 Cr
Flywings Simulator Training Centre Fund Raise of ₹68.2 Cr
Flywings Simulator's board approved Rs. 68.20 Crore fully convertible warrants on a preferential basis. Promoter Rupal Mandavia is allotted Rs. 25 Crore, subject to shareholder approval.
- Value
- ₹68.20 Cr
Kanel Industries Fund Raise of ₹16.99 Cr
Kanel Industries' board approved a rights issue of 42.52 lakh equity shares at Rs.39.95 each. The issue aggregates about Rs.16.99 Crore, with record date 13 November 2026.
- Value
- ₹16.99 Cr
- Execution
- Rights issue opens 23 November 2026 and closes 30 November 2026
Sudarshan Pharma Industries Fund Raise
Board approved issuing up to 72 Crore warrants to promoters on a preferential basis. Pricing per Reg 164 is pending, with no fixed rupee value stated.
GAIL (India) Fund Raise
GAIL Board approved in principle the IPO of subsidiary GAIL Gas Limited on Indian exchanges. GAIL will dilute its GGL equity up to 25%.